CClinicalTrials.gg
RecruitingNCT06090825Updated Oct 19, 2023

Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

An observational study in Pancreatic Cancer, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Peking Union Medical College Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
450
Sex
All
01

Study summary

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Read the detailed description

Pancreatic cancer is a highly malignant gastrointestinal tumor with only a 10% overall 5-year survival rate. More than 80% of patients are already in the advanced stage when diagnosed, losing the chance of surgery. Advanced pancreatic cancer progresses rapidly and chemoradiotherapy has limited efficacy, so palliative care is thought to play an important role in the treatment process. However, due to the late development of palliative care, there is a lack of data on real-world clinical palliative care for pancreatic cancer patients in China.

This study investigates the real-world current status of palliative care for pancreatic cancer patients by sending a web questionnaire to the doctors from the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland. The survey aims to obtain the real status of palliative care and achieve a comprehensive understanding of how to develop palliative care in hospitals.

The questionnaire includes both subjective standards like the surgeons' opinion on the development of palliative therapy and objective standards such as dedicated beds and teams for palliative care.

02

Conditions studied

  • Pancreatic Cancer

Keywords

  • follow up
  • palliative care
  • pancreatic cancer
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.

This study's planned enrollment of 450 is above the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The doctors of the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland

Inclusion criteria

  • Doctors from the General Surgery Department in Chinese public tertiary teaching hospitals and public primary care units
  • Approval to participate
  • Participants with a valid and complete questionnaire evaluated by 2 experienced surgeons

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Participants with an invalid or incomplete questionnaire
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pancreatic cancer patients

    Other: Observational study

Interventions

  • OtherObservational study

    Observational study

06

What researchers measure

Primary outcomes

  1. Descriptions and scores of real status of hospice care in different hospitals

    The primary outcome is objective standards and subjective scores of current status of palliative care to qutify the development of palliative care of different hospitals. The score is evaluated by a follow-up questionnaire. The maximum and minimum score is 10 and 0, respectively.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
    • Qiaofei Liu, MD · Contact
    • Qiaofei Liu, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06090825
Lead sponsor
Peking Union Medical College Hospital
Responsible party
Qiaofei Liu (Department director assistant, clinical chief professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Oct 19, 2023
Start date
Sep 1, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Oct 19, 2023

Study contacts

Qiaofei Liu
Contact
qfliu@aliyun.com
8615201693370
Yuze Hua
Contact
huayuze97@163.com
8617813719961
Qiaofei Liu
study chair · Department of General Surgery, Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion